37 results about "HUMAN THYMUS" patented technology

The present invention belongs to the field of pharmacy and cell biology, and relates to an efficient and reliable high content CCR4 antagonist screening cell model using human chemokine receptor 4 as a target, and a screening method thereof. According to the present invention, a cell line being subjected to human CCR4-enhanced green fluorescent protein fusion expression introducing is established, excitation is performed through human thymus activation regulated chemokine and human macrophage chemotatic factor, the CCR4 with green fluorescent protein is induced to produce re-distribution so as to form green fluorescent particles, and the CCR4 antagonist screening cell model for high-content screening is established; the bioactivity of the compound is evaluated by determining the CCR4 green fluorescent particle formation excited or inhibited by the screened compound through the model; and the established drug screening model is the sensitive, efficient and reliable CCR4 antagonist screening cell model suitable for high-throughput and high-content screening, and the method is the sensitive, efficient and reliable method suitable for high-throughput and high-content screening.

This application provides an anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody and its application. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody of the present application comprises three heavy chain complementarity determining regions (CDR‑H1, CDR‑H2 and CDR‑H3) and three light chain complementarity determining regions (CDR‑L1 , CDR‑L2 and CDR‑L3), wherein, (a) the amino acid sequence of CDR‑H1 is shown in SEQ ID NO: 1; (b) the amino acid sequence of CDR‑H2 is shown in SEQ ID NO: 2; (c ) The amino acid sequence of CDR‑H3 is shown in SEQ ID NO: 3; (d) the amino acid sequence of CDR‑L1 is shown in SEQ ID NO: 4; (e) the amino acid sequence of CDR‑L2 is shown in SEQ ID NO: 5 and (f) the amino acid sequence of CDR-L3 is shown in SEQ ID NO:6. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, compared with the anti-human TSLP monoclonal antibody Tezepelumab (expressed and prepared according to the sequence disclosed in the patent), has comparable affinity for binding human TSLP, and is in the cell level. It is more active than Tezepelumab and is expected to show good clinical effects in the prevention and treatment of related diseases.

The invention discloses a method for establishing a PDX (Patient Derived Xenograft) model of human blood tumor. The method comprises the steps of extracting a blood tumor cell of a patient, adding rabbit anti-human thymocyte immunoglobulin ATG (Anti-Thymocyte Globulin) and patient autologous serum, mixing, incubating and after completing the incubation, re-suspending the obtained cell and inoculating in a mouse; and feeding the inoculated mouse with CsA (Cyclosporine A) and lasting for 5-10 days starting from 2 days before the inoculation of the blood tumor cell. The method disclosed by the invention has the beneficial effects that a novel highly immunodeficient NCG mouse independently developed in China is firstly adopted to establish a human leukemia PDX model; by orally taking human thymocyte immunoglobulin pretreatment sample combined with the cyclosporine for a long term, donor-derived T cells are removed and inhibited; and by combining the toxic effect of the ATG on lymphocytes with the functional blocking effect of the CsA on T lymphocytes, the immune function of the T lymphocytes can be persistently inhibited and the success rate of PDX modeling of the blood tumor is significantly improved.

A recombinant plasmid with human extrasin beta4-gene carrier is prepared by inserting human extrasin beta4-gene into eukaryote expression starter to construct recombinant plasmid, entering it into striped muscle cell, synthesizing T beta-4 by cell protein synthetic system and secreting to extracellular region. It can improve wound healed, prevent cell from death and be used to repair skin and heart damages.

The invention relates to the technical field of antibodies, in particular to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody provided by the present invention can specifically bind hTSLP with high affinity, and can effectively inhibit the binding of TSLP to its receptor, thereby inhibiting TSLP from activating downstream signaling pathways and activating immune cells. The TSLP antibody provided by the present invention is used for the content detection of hTSLP and allergic asthma, chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic sinusitis, eosinophilic esophagitis, allergic conjunctivitis, inflammatory bowel disease It is of great significance in the diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as atopic dermatitis or atopic dermatitis.

The application discloses a method for preparing a concentrated solution of anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, comprising the following steps: Concentrate the solution to obtain the first concentrated sample; Step 2: Replace the first concentrated sample with a buffer solution to obtain a replacement concentrated solution; Step 3: Mix the replaced concentrated solution and the mother liquor of the amino acid protective agent to obtain a mixed solution, and the The above mixed solution was concentrated by ultrafiltration to obtain a second concentrated sample. The preparation method described in this application can reduce the viscosity of high-concentration antibody drug solution and improve the stability. The method is simple and easy, and can be scaled up for production, which can ensure the high purity of the sample and obtain a high recovery rate.

The invention relates to a kit used for diagnosing the acute exacerbation period of chronic obstructive pulmonary disease. The kit comprises a cell factor and an enzyme labeled antibody thereof and is characterized in that the cell factor is interleukin 9, interleukin 18 binding protein A, C-C sequence ligand 28, a human skin T cell capture chemokine, a Beta cytokine, a monocyte chemoattractant protein-3, a monocyte chemoattractant protein-4, a lymphotoxin induced protein entering the T cell, a macrophage-derived chemokine, a human bone marrow suppression factor 1, a human macrophage stimulating protein, an osteopontin and a human thymus expressed chemokine. The invention firstly proposes that the cell factor can be used as a leading indicator for diagnosis of the acute exacerbation period of the chronic obstructive pulmonary disease.